InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Canada: Tribunal dismisses Eli Lilly’s NAFTA challenge




Following the invalidation of its patents for Strattera (atomoxetine) and Zyprexa (olanzapine), Eli Lilly and Company submitted claims to international arbitration under the North American Free Trade Agreement (NAFTA). On March 1, 2017, the Tribunal issued its final award dismissing Eli Lilly's claims.

Eli Lilly's patents were invalidated on the basis of the so-called "promise of the patent" doctrine; namely, that the claims of the patent failed to deliver utility promised by statements in the specification. Eli Lilly argued that Canadian courts had dramatically changed the application of the utility requirement through a series of cases that adopted the promise doctrine and that the retroactive application of this doctrine to Eli Lilly's patents resulted in a breach of Canada's obligations under NAFTA.

The Tribunal, however, found that Canada's utility requirement underwent incremental and evolutionary changes between the grant of the patents and their subsequent invalidation. Moreover, it found that the promise standard has a "strong foundation" in earlier jurisprudence of the Supreme Court of Canada. Further, the Tribunal found that the doctrine was neither arbitrary nor discriminatory. In summary, the government of Canada was not found to have violated its obligations under NAFTA.

The NAFTA decision further supports the application of the heightened utility requirement that may arise under Canadian law through application of the promise doctrine. Those interested in the issue, however, eagerly await a decision from the Supreme Court of Canada in the case of AstraZeneca Canada Inc v Apotex Inc. In that case, which was heard in November 2016, the promise doctrine was directly before the Supreme Court. A decision, which may bring some clarity on the issue, is expected soon.

Neil Padgett

Smart & Biggar/ Fetherstonhaugh
55 Metcalfe Street Suite 900
PO Box 2999 Station D
Ottawa ON  K1P 5Y6
Tel: 613 232 2486
Fax: 613 232 8440 
ottawa@smart-biggar.ca
www.smart-biggar.ca


Comments






profile

Managing IP

ManagingIP

ManagingIP profile

Rich pickings: how Hollywood rivals will profit from Weinstein's downfall https://t.co/3v4ZamycWP Analysis of Weinstein Co IP via @guardian

Oct 20 2017 03:32 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @BakerMcK_LonIP: Read @BakerIPnewsDACH and @BakerMcK_LonIP summary in @ManagingIP on the BGH's #3D chocolate packaging decision 🍫🇩🇪🇬🇧htt…

Oct 20 2017 02:28 ·  reply ·  retweet ·  favourite
ManagingIP profile

Bea Swedlow takes over from Randi Karpinia as @WomenInIP Committee chair at #aiplaAM17 - "Randi keeps me in check + I keep her out of check!

Oct 20 2017 11:57 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


null null null

October 2017

Courts grapple with scope of patent protection

The Supreme Court’s decision in Actavis v Eli Lilly introduced a doctrine of equivalents and arguably also established a doctrine of prosecution history estoppel in the UK. We look at the law across Europe, and the impact the decision might have. Kingsley Egbuonu, Michael Loney and James Nurton set the scene



Most read articles

Supplements